Business, energy, technology, markets and global industry news from Business News Today

Wegovy

PharmaDeviceNews Wegovy
Novellia’s GLP-1 and Metabolic Health Registry aims to track weight outcomes, treatment persistence and coverage disruptions across complex patient journeys, addressing evidence gaps left by traditional healthcare datasets. Representative image.
Pharma & Biotech

Novellia’s GLP-1 registry found a surprising weight-loss pattern, but what does it really prove?

See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.

Read More
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Pharma & Biotech

Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada

Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.

Read More
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test

AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.

Read More
Representative image of a clinical weight-management consultation with an injection pen and progress chart, reflecting Pfizer’s berobenatide Phase 2b data and the growing race to develop monthly GLP-1 obesity treatments.
Pharma & Biotech

Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus

Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Pharma & Biotech

How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution

Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.

Read More
Pharma & Biotech

What Veru Inc.’s Phase 2b PLATEAU trial signals about the evolution of combination obesity drugs

Veru Inc. launches Phase 2b PLATEAU trial combining enobosarm with semaglutide for obesity. Discover what it means for next-generation weight-loss drugs.

Read More
Pharma & Biotech

Novo Nordisk secures EU nod for higher Wegovy dose amid intensifying GLP-1 competition

EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.

Read More
Pharma & Biotech

Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?

Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.

Read More